SCHEMBL3558182

SCHEMBL3558182

O=[N+]([O-])c1cc2c(c3ccc(-c4ccccc4O)cc13)C(CCl)CN2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.35
MEN1 O00255 4/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 3/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 7/20 0.33
KDR P35968 2/20 0.33
GAA P10253 3/20 0.32
NPSR1 Q6W5P4 2/20 0.32
MAPK1 P28482 2/20 0.32
QPCT Q16769 1/20 0.31
QPCTL Q9NXS2 1/20 0.31
LMNA P02545 2/20 0.30
KDM4E B2RXH2 1/20 0.30
HTT P42858 1/20 0.30
MCL1 Q07820 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
ADH1A P07327 1/20 0.30
KIT P10721 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563974 0.82 CTSB (0.41) KMT2AMEN1ALDH1A1HPGDRAB9A
SCHEMBL3568374 0.79 ALDH1A1 (0.37) KMT2AMEN1ALDH1A1HPGDRAB9A
SCHEMBL13460619 0.78 TSHR (0.38) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL3562579 0.78 VCAM1 (0.45) KMT2AALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL3570106 0.77 PARP1 (0.40) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL13369379 0.75 KMT2A (0.38) KMT2AMEN1ALDH1A1HPGDRAB9A
SCHEMBL3560629 0.75 VCAM1 (0.42) KMT2AMEN1MAPTMAPK1LMNA
SCHEMBL3563670 0.75 CA1 (0.45) ALDH1A1HPGDMAPTMAPK1LMNA
SCHEMBL13853540 0.74 CYP1A2 (0.31) MAPK1
SCHEMBL3558765 0.74 VCAM1 (0.41) KMT2AMEN1ALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A KMT2A 1807/4885MEN1 3844/4885ALDH1A1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.